Five-year probability of AML was 49%, 16%, and 13% for MF with TP53, chromatin/spliceosome mutation, and JAK2 homozygous mutation, respectively (p = 0.001 for the comparison according to molecular classification, Figure 4). This evidence concerns the gene JAK2 and acute myeloid leukemia.